• español
    • English
  • Login
  • español 
    • español
    • English

UniversidaddeCádiz

Área de Biblioteca, Archivo y Publicaciones
Comunidades y colecciones
Ver ítem 
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/37032

DOI: 10.3389/FPSYT.2024.1497565

ISSN: 1664-0640

Ficheros
OA_2025_0235.pdf (1.655Mb)
Estadísticas
Ver estadísticas
Métricas y Citas
 
Compartir
Exportar a
Exportar a MendeleyRefworksEndNoteBibTexRIS
Metadatos
Mostrar el registro completo del ítem
Autor/es
Mas, Sergi; Julià, Laura; Cuesta, Manuel J.; Crespo Facorro, Benedicto; Vázquez Bourgon, Javier; Spuch, Carlos; González-Pinto, Ana; Ibáñez, Angela; Usall, Judith; Romero López Alberca, CristinaAutoridad UCA; Catalan, Ana; Mané, Anna; Bernardo, Miquel
Fecha
2024
Departamento/s
Psicología
Fuente
Frontiers in Psychiatry - 2024, Vol. 15
Resumen
The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the “Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes” study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from “Clinical Program on Early Phases of Psychosis” (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.
Materias
antipsychotic; personalized medicine; Pharmacogenetics; prediction; psychosis
Colecciones
  • Artículos Científicos [12014]
Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional

Listar

Todo RODINComunidades y ColeccionesPor fecha de publicaciónAutoresTítulosMateriasEsta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Mi cuenta

AccederRegistro

Estadísticas

Ver Estadísticas de uso

Información adicional

Acerca de...Deposita en RODINPolíticasNormativasDerechos de autorEnlaces de interésEstadísticasNovedadesPreguntas frecuentes

RODIN está accesible a través de

OpenAIREOAIsterRecolectaHispanaEuropeanaBaseDARTOATDGoogle Académico

Enlaces de interés

Sherpa/RomeoDulcineaROAROpenDOARCreative CommonsORCID

RODIN está gestionado por el Área de Biblioteca, Archivo y Publicaciones de la Universidad de Cádiz

ContactoSugerenciasAtención al Usuario